MINAXI HIMANSHU PATEL, KAMAL VIMALBHAI KANODIA, HIMANSHU VALLABHBHAI PATEL AND RASHMI DALSUKHBHAI PATEL
Abstract
Patients with kidney diseases particularly on dialysis and post renal transplant patients have a higher tendency to develop MTB infection and its Rifampicin Resistance. The purpose of the study was to determine whether or not patients with chronic kidney disease and those who had undergone a renal transplant had MTB infection and whether or not it was resistant to rifampicin. The Department of Pathology and Lab Medicine, Transfusion services, and Immunohematology conducted this study, which is a retrospective record-based data analysis study carried out in the Department. At the IKDRC-ITS, the research was carried out over the course of approximately two and a half years. The study included a total of fifty cases of presumed tuberculosis that were identified through the use of the Xpert MTB/RIF assay. The extrapulmonary samples that were collected included ascitic fluid, pleural fluid, pericardial fluid, pus, tissue, cerebrospinal fluid, lymph nodes, bone marrow, and urine. In order to identify MTB DNA and Rifampicin resistance, the samples were subjected to automated real-time polymerase chain reaction (Gene Xâpert) tests. Among these fifty MTB-positive samples, the maximum number of patients was twenty between the ages of 21 and 40, fourteen between the ages of 41 and 60, eight patients older than sixty, and eight patients younger than twenty years. Rifampicin sensitivity was discovered in 49 of the individual patients. Within the population of patients who have received a renal transplant, the incidence of MTB infection, also known as pulmonary tuberculosis, is quite high. Greater sensitivity in detecting M. tuberculosis complex and rifampicin resistance can be achieved through the use of the GeneXpert® test, which is a real-time PCR technique that is both straightforward and quickly performed.